Fore Biotherapeutics
Philadelphia, PA, United States · Biotechnology, Health Care, Therapeutics · 48 employees
Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and devel
Funding history
- Funding Round — $37.4M — May 2025
- Series series d — $75.0M — Aug 2023
- Funding Round — $62.1M — Aug 2023
Recent signals
- May 15, 2025: Raised $37.4M
- Jan 09, 2025: Launched FORE Biotherapeutics Announces Pipeline Achievements and Strategic Goals for 2025 at J.P. Morgan Healthcare Conference.
- Aug 12, 2024: FORE Biotherapeutics Appoints Michael Byrnes as Chief Financial Officer
- Aug 24, 2023: Raised $75.0M in Series series d
- Aug 24, 2023: Raised $62.1M
See plans & pricing → Track Fore Biotherapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.